Article Abstract:
Hormone replacement therapy may lower a woman's risk of hip fracture, according to a review of 22 clinical trials. However, this beneficial effect was seen predominantly in women under the age of 60.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
The drug alendronate may reduce the risk of bone fractures in postmenopausal women with osteoporosis. Researchers tested the drug on 1,102 postmenopausal women with osteoporosis, while 590 similar women took a placebo. After three years, 9% of the women taking alendronate had fractured a bone at a site other than the spine, compared to 12.6% of the women in the placebo group. Alendronate reduced the risk of bone fractures by about 30%. Osteoporosis causes 1.5 million fractures in the US each year and this number may increase as the population ages.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
The bisphosphonate drug risedronate appears to be effective in reducing the risk of bone fracture in postmenopausal women with osteoporosis. Researchers randomly assigned 2,458 postmenopausal women with at least one previous bone fracture to take risedronate or a placebo for up to 3 years. Over the 3-year period, the drug reduced the rate of spinal fractures by 41% and the rate of other fractures by 39%. Bone density also increased in the women who took the drug compared to those who took a placebo.
User Contributions:
Comment about this article or add new information about this topic: